Tanespimycin

The opportunities and challenges of targeting heat shock protein 90

Charles Erlichman

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: Heat shock protein 90 (HSP90) is the core of a multi-chaperone complex critical for the folding, trafficking, and stabilization of many client proteins that are involved in tumor cell proliferation, survival, and angiogenesis. Targeting HSP90 results in degradation of these client proteins. Objective: Data supporting the development of tanespimycin, which targets HSP90, are reviewed. Methods: Clinical data available for tanespimycin development are presented. Results: Tanespimycin can be given safely at biologically active doses with mild toxicity such as nausea, vomiting, diarrhea, and fatigue. Although single-agent studies have shown limited activity, combinations of tanespimycin with bortezomib or trastuzumab have suggested promising avenues of further evaluation in multiple myeloma and breast cancer, respectively. Conclusions: Further development of HSP90-targeted strategies include testing of novel chemical structures having better solubility and stability and the potential for oral administration. Targeting of HSP90 in combination with other heat shock proteins, such as HSP70 or HSP27, may be an alternative strategy that warrants further exploration.

Original languageEnglish (US)
Pages (from-to)861-868
Number of pages8
JournalExpert Opinion on Investigational Drugs
Volume18
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

tanespimycin
HSP90 Heat-Shock Proteins
Heat-Shock Proteins
Multiple Myeloma
Solubility
Nausea
Proteolysis
Vomiting
Fatigue
Oral Administration
Diarrhea
Cell Survival
Cell Proliferation
Breast Neoplasms

Keywords

  • 17-AAG
  • Heat shock protein
  • HSP90
  • Tanespimycin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Tanespimycin : The opportunities and challenges of targeting heat shock protein 90. / Erlichman, Charles.

In: Expert Opinion on Investigational Drugs, Vol. 18, No. 6, 06.2009, p. 861-868.

Research output: Contribution to journalArticle

@article{2915100844dd42fd905c353d4506a53c,
title = "Tanespimycin: The opportunities and challenges of targeting heat shock protein 90",
abstract = "Background: Heat shock protein 90 (HSP90) is the core of a multi-chaperone complex critical for the folding, trafficking, and stabilization of many client proteins that are involved in tumor cell proliferation, survival, and angiogenesis. Targeting HSP90 results in degradation of these client proteins. Objective: Data supporting the development of tanespimycin, which targets HSP90, are reviewed. Methods: Clinical data available for tanespimycin development are presented. Results: Tanespimycin can be given safely at biologically active doses with mild toxicity such as nausea, vomiting, diarrhea, and fatigue. Although single-agent studies have shown limited activity, combinations of tanespimycin with bortezomib or trastuzumab have suggested promising avenues of further evaluation in multiple myeloma and breast cancer, respectively. Conclusions: Further development of HSP90-targeted strategies include testing of novel chemical structures having better solubility and stability and the potential for oral administration. Targeting of HSP90 in combination with other heat shock proteins, such as HSP70 or HSP27, may be an alternative strategy that warrants further exploration.",
keywords = "17-AAG, Heat shock protein, HSP90, Tanespimycin",
author = "Charles Erlichman",
year = "2009",
month = "6",
doi = "10.1517/13543780902953699",
language = "English (US)",
volume = "18",
pages = "861--868",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Tanespimycin

T2 - The opportunities and challenges of targeting heat shock protein 90

AU - Erlichman, Charles

PY - 2009/6

Y1 - 2009/6

N2 - Background: Heat shock protein 90 (HSP90) is the core of a multi-chaperone complex critical for the folding, trafficking, and stabilization of many client proteins that are involved in tumor cell proliferation, survival, and angiogenesis. Targeting HSP90 results in degradation of these client proteins. Objective: Data supporting the development of tanespimycin, which targets HSP90, are reviewed. Methods: Clinical data available for tanespimycin development are presented. Results: Tanespimycin can be given safely at biologically active doses with mild toxicity such as nausea, vomiting, diarrhea, and fatigue. Although single-agent studies have shown limited activity, combinations of tanespimycin with bortezomib or trastuzumab have suggested promising avenues of further evaluation in multiple myeloma and breast cancer, respectively. Conclusions: Further development of HSP90-targeted strategies include testing of novel chemical structures having better solubility and stability and the potential for oral administration. Targeting of HSP90 in combination with other heat shock proteins, such as HSP70 or HSP27, may be an alternative strategy that warrants further exploration.

AB - Background: Heat shock protein 90 (HSP90) is the core of a multi-chaperone complex critical for the folding, trafficking, and stabilization of many client proteins that are involved in tumor cell proliferation, survival, and angiogenesis. Targeting HSP90 results in degradation of these client proteins. Objective: Data supporting the development of tanespimycin, which targets HSP90, are reviewed. Methods: Clinical data available for tanespimycin development are presented. Results: Tanespimycin can be given safely at biologically active doses with mild toxicity such as nausea, vomiting, diarrhea, and fatigue. Although single-agent studies have shown limited activity, combinations of tanespimycin with bortezomib or trastuzumab have suggested promising avenues of further evaluation in multiple myeloma and breast cancer, respectively. Conclusions: Further development of HSP90-targeted strategies include testing of novel chemical structures having better solubility and stability and the potential for oral administration. Targeting of HSP90 in combination with other heat shock proteins, such as HSP70 or HSP27, may be an alternative strategy that warrants further exploration.

KW - 17-AAG

KW - Heat shock protein

KW - HSP90

KW - Tanespimycin

UR - http://www.scopus.com/inward/record.url?scp=67649625171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649625171&partnerID=8YFLogxK

U2 - 10.1517/13543780902953699

DO - 10.1517/13543780902953699

M3 - Article

VL - 18

SP - 861

EP - 868

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 6

ER -